Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis

被引:0
|
作者
Sato E. [1 ]
Kamijo-Ikemori A. [2 ,4 ]
Oikawa T. [3 ]
Okuda A. [3 ]
Sugaya T. [3 ,4 ]
Kimura K. [5 ]
Nakamura T. [1 ,4 ]
Shibagaki Y. [4 ]
机构
[1] Division of Nephrology, Department of Medicine, Shinmatsudo Central General Hospital, 1-380 Shinmatsudo, Matsudo,Chiba
[2] Department of Anatomy, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki,Kanagawa
[3] Cmic Holdings Co. Ltd., Hamamatsucho Bldg., 1-1-1 Shibaura, Minato-ku, Tokyo
[4] Department of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki, 216-8511, Kanagawa
[5] Department of Internal Medicine, Japan Community Health Care Organization, Tokyo Takanawa Hospital, Tokyo
关键词
AKI; Biomarker; L-FABP; Oxidative stress; POC; Sepsis;
D O I
10.1186/s41100-017-0107-x
中图分类号
学科分类号
摘要
Sepsis due to microbial invasion often causes multiple organ failure (MOF), including acute kidney injury (AKI), with high mortality rates in serious cases. Hence, there is an urgent need for diagnostic biomarkers that can be used to rapidly, accurately, and easily detect sepsis to identify the condition early and guide the selection of appropriate treatment. Liver-type fatty acid-binding protein (L-FABP), which localizes in renal proximal tubules, is excreted into the urine in response to oxidative stress-induced tubular injury. Because of this mechanism, L-FABP has been reported to be a useful urinary biomarker not only for renal disease but also for the severity of sepsis. Based on this concept, we developed a new L-FABP point-of-care (POC) assay kit that can be used to rapidly measure human L-FABP in the urine to further improve the usefulness of this biomarker in clinical settings. In this review, we describe the molecular mechanisms of L-FABP, its clinical usefulness, and the performance of the POC assay kit. © 2017 The Author(s).
引用
收藏
相关论文
共 50 条
  • [21] Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury
    Ferguson, Michael A.
    Vaidya, Vishal S.
    Waikar, Sushrut S.
    Collings, Fitz B.
    Sunderland, Kelsey E.
    Gioules, Costas J.
    Bonventre, Joseph V.
    KIDNEY INTERNATIONAL, 2010, 77 (08) : 708 - 714
  • [22] Urinary liver-type fatty acid-binding protein predicts recovery from acute kidney injury
    Wang, Liang
    Xue, Jing
    Chen, Caimei
    Zhang, Zhijian
    Deng, Zhaohong
    Sun, Zhuxing
    Xing, Changying
    CLINICAL NEPHROLOGY, 2015, 84 (05) : 255 - 261
  • [23] Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis
    Zhang, Li
    Xue, Shuai
    Wu, Meiyan
    Dong, Dan
    FRONTIERS IN MEDICINE, 2022, 9
  • [24] Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs
    Takashima, Satoshi
    Nagamori, Yumiko
    Ohata, Keiichi
    Oikawa, Tsuyoshi
    Sugaya, Takeshi
    Kobatake, Yui
    Nishii, Naohito
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2021, 83 (09): : 1465 - 1471
  • [25] Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial
    Kamijo, A
    Sugaya, T
    Hikawa, A
    Yamanouchi, M
    Hirata, Y
    Ishimitsu, T
    Numabe, A
    Takagi, M
    Hayakawa, H
    Tabei, F
    Sugimoto, T
    Mise, N
    Kimura, K
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2005, 145 (03): : 125 - 133
  • [26] Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD
    Matsui, Katsuomi
    Kamijo-Ikemori, Atsuko
    Imai, Naohiko
    Sugaya, Takeshi
    Yasuda, Takashi
    Tatsunami, Shinobu
    Toyama, Tadashi
    Shimizu, Miho
    Furuichi, Kengo
    Wada, Takashi
    Shibagaki, Yugo
    Kimura, Kenjiro
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2016, 20 (02) : 195 - 203
  • [27] Clinical Significance of Urinary Liver-Type Fatty Acid-Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients
    Kamijo-Ikemori, Atsuko
    Sugaya, Takeshi
    Yasuda, Takashi
    Kawata, Takehiro
    Ota, Akio
    Tatsunami, Shinobu
    Kaise, Ruriko
    Ishimitsu, Toshihiko
    Tanaka, Yasushi
    Kimura, Kenjiro
    DIABETES CARE, 2011, 34 (03) : 691 - 696
  • [28] Distinct Roles of Urinary Liver-Type Fatty Acid-Binding Protein in Non-Diabetic Patients with Anemia
    Imai, Naohiko
    Yasuda, Takashi
    Kamijo-Ikemori, Atsuko
    Shibagaki, Yugo
    Kimura, Kenjiro
    PLOS ONE, 2015, 10 (05):
  • [29] Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD
    Katsuomi Matsui
    Atsuko Kamijo-Ikemori
    Naohiko Imai
    Takeshi Sugaya
    Takashi Yasuda
    Shinobu Tatsunami
    Tadashi Toyama
    Miho Shimizu
    Kengo Furuichi
    Takashi Wada
    Yugo Shibagaki
    Kenjiro Kimura
    Clinical and Experimental Nephrology, 2016, 20 : 195 - 203
  • [30] Urinary Excretion of Liver Type Fatty Acid Binding Protein Accurately Reflects the Degree of Tubulointerstitial Damage
    Yokoyama, Takeshi
    Kamijo-Ikemori, Atsuko
    Sugaya, Takeshi
    Hoshino, Seiko
    Yasuda, Takashi
    Kimura, Kenjiro
    AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (06): : 2096 - 2106